M-EZETIMIBE TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
30-05-2023
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
EZETIMIBE
Inapatikana kutoka:
MANTRA PHARMA INC
ATC kanuni:
C10AX09
INN (Jina la Kimataifa):
EZETIMIBE
Kipimo:
10MG
Dawa fomu:
TABLET
Tungo:
EZETIMIBE 10MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
100/500
Dawa ya aina:
Prescription
Eneo la matibabu:
CHOLESTEROL ABSORPTION INHIBITORS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0149164001; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2017-08-18
Tabia za bidhaa
Page
1
of
30
PRODUCT MONOGRAPH
PR
M-EZETIMIBE
Ezetimibe Tablets, USP
10 mg
Cholesterol Absorption Inhibitor
Mantra Pharma Inc.,
1000 du Lux, suite 201
Brossard, Quebec
J4Y 0E3
Control # 275104
Date
of
Revision:
MAY
30, 2023
Page
2
of
30
TABLE OF CONTENT
Table of Content
.....................................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................3
SUMMARY PRODUCT INFORMATION
...........................................................................................3
INDICATIONS AND CLINICAL USE
............................................................................................3
CONTRAINDICATIONS
.................................................................................................................4
WARNINGS AND PRECAUTIONS
................................................................................................4
ADVERSE REACTIONS
.................................................................................................................7
DRUG INTERACTIONS
................................................................................................................11
DOSAGE AND ADMINISTRATION
............................................................................................13
OVERDOSAGE
..............................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
..........................................................................14
STORAGE AND STABILITY
........................................................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
...........................................................16
PART II: SCIENTIFIC INFORMATION
............................................................................................17
PHARMACEUTICAL INFORMATION
.......
Soma hati kamili
